Sparks fly in advance of FDA meeting to examine Bayer contraceptives
This article was originally published in Scrip
Executive Summary
Meetings of the US FDA's Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committees often have been controversial, and the one being convened on 8 December to review cardiovascular safety concerns involving four Bayer Healthcare oral contraceptives containing drospirenone is shaping up to be no different.